Matinas Biopharma Appoints Evelyn D’An as Director and Audit Committee Chair

BEDMINSTER, N.J. (February 7, 2025) – Matinas Biopharma Holdings, Inc. (NYSE American: MTNB) announced today that Evelyn D’An has been appointed to its Board of Directors as an independent director and Chair of the Audit Committee, effective February 5, 2025.

The appointment of Ms. D’An was made by the Board of Directors of Matinas BioPharma Holdings, Inc., a Delaware corporation, based on the recommendation of its Nominating and Corporate Governance Committee. Ms. D’An will also serve as a member of the Nominating and Corporate Governance Committee within the company.

As per the Board’s assessment, Ms. D’An qualifies as an independent director under the rules of The NYSE American LLC, meets the heightened standards of independence for compensation and audit committee membership set by the U.S. Securities and Exchange Commission (SEC) and NYSE, and is recognized as an “audit committee financial expert” in accordance with the criteria in Regulation S-K.

Ms. D’An brings a wealth of experience to the role, having served as a board director and financial leader across various industries. She is the President of D’An Financial Services and has been actively involved in corporate governance, financial oversight, and accounting since 2004. Ms. D’An’s prior tenure at Ernst & Young, a notable accounting and professional services firm, further bolsters her expertise in financial matters.

In terms of her board affiliations, Ms. D’An currently serves on the boards of Zoomcar Holdings, Inc. (NASDAQ: ZCAR), GHD Group Pty Ltd., and Backblaze, Inc. (NASDAQ: BLZE), where she holds positions on audit, compensation, and nominating committees. She was also a board member of Renovaro Inc. (NASDAQ: REND) until June 2021. Ms. D’An holds a B.S. in Accounting from the State University at Albany.

The Company has stated that Ms. D’An will receive compensation in line with its standard non-employee director compensation plan. There are no undisclosed arrangements or related party transactions between Matinas Biopharma and Ms. D’An that warrant reporting under Item 404(a) of Regulation S-K.

A press release issued by the Company on February 7, 2025, announced Ms. D’An’s appointment. Further details about this announcement can be found in Exhibit 99.1 attached to the SEC filing.

Matinas BioPharma is a biopharmaceutical company dedicated to developing innovative therapies utilizing its lipid nanocrystal (LNC) platform delivery technology. For more information about Matinas BioPharma, please visit www.matinasbiopharma.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including predictions regarding Ms. D’An’s appointment. Investors are advised to consider the risk factors associated with such statements detailed in the Company’s SEC filings.

Contact:
Jerome D. Jabbour
Chief Executive Officer
(908) 484-8805
[email protected]

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Matinas Biopharma’s 8K filing here.

About Matinas Biopharma

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company’s LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.